- Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997; 39: 1–14.
- Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Ag Chemother 1993; 37: 349–53.
- Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering Jr RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Ag Chemother 1993; 37: 366–70.
- Child J, Andrews J, Boswell F, Brenwald N, Wise R. The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. J Antimicrob Chemother 1995; 35: 869–76.
- Verbist L, Verhaegen J. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. Eur J Clin Microbiol Infect Dis 1996; 15: 683–5.
- Martínez-Martínez L, Joyanes P, Pascual A, Terrero E, Perea EJ. Activity of eight fluoroquinolones against enterococci. Clin Microbiol Infect 1997; 3: 497–9.
- Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995; 35: 230–2.
- Klugman K, Wasas A. In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. J Antimicrob Chemother 1995; 36: 873–4.
- Knapp JS, Neal SW, Parekh MC, Rice RJ. In vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neisseria gonorrhoeae. Antimicrob Ag Chemother 1995; 39: 987–9.
- Bonilla HF, Zarins LT, Bradley SF, Kauffman CA. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagnostic Microbiol Infect Dis 1996; 26: 17–21.
- Dembry LM, Farrel PA, Orcutt DR, Gerrity LA, Andriole VT. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest. J Antimicrob Chemother 1997; 39: 35–42.
- Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Ag Chemother 1997; 41: 2312–6.
- Olsson-Liljequist B, Hoffman BM, Hedlund J. Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden. Eur J Clin Microbiol Infect Dis 1996; 15: 671–5.
- NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th edn, Approved Standard. M7-A4. NCCLS, Wayne, PA, USA 1997; 17: 1–29.
- Björklind A, Ringertz S, Kronvall G. Types of interpretive errors in susceptibility testing. APMIS 1989; 97: 941–8.
- Olsson-Liljequist B, Larsson P, Walder M, Miörner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis 1997; Suppl 105: 13–23.
- Ringertz S, Olsson-Liljequist B, Kahlmeter G, Kronvall G. Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance. Scand J Infect Dis 1997; Suppl 105: 8–12.
- Kronvall G. Response to Drs Ian Phillips and Anna King. Clin Microbiol Infection 1998; 4: 232.
- Kronvall G, Rylander M, Walder M, Lind-Brandberg L, Larsson P, Törnqvist E, et al. Calibration of disk diffusion antibiotic susceptibility testing. Calculation of species-related trovafloxacin interpretive zone breakpoints for the individual laboratory and aspects on the selection of disk potency. Scand J Infect Dis 1999; 31: 573–8.
- Edelstein PH. Antimicrobial chemotherapy for Legionnaires disease: time for a change. Ann Intern Med 1998; 129: 328–30.
- Fuchs PC, Barry AL, Brown SD. Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagnostic Microbiol Infect Dis 1996; 26: 23–7.
- Evans ME, Titlow WB. Selection of fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus with ciprofloxacin and trovafloxacin. Antimicrobial Ag Chemother 1998; 42: 727.
- M’Zali FH, Nice C, Dalhoff A, et al. Differential selection of quinolone resistance by new quinolones in methicillin-sensitive (MSSA) and -resistant (MRSA) Staphylococcus aureus. Abstract P130. Clin Microbiol Infection 1999; 5: Suppl 3: 119–20.
Trovafloxacin Susceptibility of Aerobic Clinical Bacterial Isolates from Sweden
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.